Significant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.
Catherine Tak Piech
Advertisement
Catherine Tak Piech spent more than 30 years as an executive in big pharma, and is now with a strategy consultant with Genesis Research LLC, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services.
Articles by Catherine Tak Piech
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
2
Lilly Forms Partnership with NVIDIA to Create AI Supercomputer
3
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
4
FDA Announces New Biosimilar-Targeted Draft Guidance
5
